Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -14,961 | -34,682 | -20,253 | -13,670 | -7,250 |
| Depreciation Amortization | -1,789 | 319 | 20 | 13 | 50 |
| Accounts receivable | N/A | N/A | -328 | N/A | N/A |
| Other Working Capital | 2,071 | -12,754 | -550 | -944 | 12 |
| Other Operating Activity | 2,250 | 7,039 | 1,530 | 702 | 263 |
| Operating Cash Flow | $-12,429 | $-40,078 | $-19,581 | $-13,899 | $-6,925 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -111,353 | N/A | N/A | N/A | N/A |
| PPE Investments | -193 | -199 | -73 | -43 | -21 |
| Investing Cash Flow | $-111,546 | $-199 | $-73 | $-43 | $-21 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,319 | 570 | 287 | 287 | N/A |
| Other Financing Activity | 0 | 190,162 | -3,374 | -1,818 | -908 |
| Financing Cash Flow | $1,319 | $190,732 | $-3,087 | $-1,531 | $-908 |
| Beginning Cash Position | 210,518 | 60,063 | 60,063 | 60,063 | 60,063 |
| End Cash Position | 87,862 | 210,518 | 37,322 | 44,590 | 52,209 |
| Net Cash Flow | $-122,656 | $150,455 | $-22,741 | $-15,473 | $-7,854 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,429 | -40,078 | -19,581 | -13,899 | -6,925 |
| Capital Expenditure | -193 | -199 | -73 | -43 | -21 |
| Free Cash Flow | -12,622 | -40,277 | -19,654 | -13,942 | -6,946 |